The Effect of Mannitol Volume with Changes in Osmolarity in Traumatic Brain Injury
NCT ID: NCT06846307
Last Updated: 2025-03-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
32 participants
INTERVENTIONAL
2023-11-01
2024-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Correlation of Measured and Calculated Serum Osmolality During Hyperosmolar Drugs Infusion in Patients After Craniotomy
NCT02037815
Effect of Mannitol 20% Versus Hypertonic Saline 7.5% in Brain Metabolism and Oxygenation
NCT03573999
Osmotic Therapy for Treatment of Intracranial Hypertension for Traumatic Brain Injury
NCT01215019
Neuroprotective Effect of Dexomitomidine
NCT05487742
Normothermia in Patients With Acute Cerebral Damage
NCT00491192
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mannitol 1
mannitol 3x125 cc
Mannitol
mannitol administration across all three dosages (3x125 cc, 2x250 cc, 3x250 cc) given as an IV drip for 15-20 minutes
Mannitol 2
Mannitol 2x250 cc
Mannitol
mannitol administration across all three dosages (3x125 cc, 2x250 cc, 3x250 cc) given as an IV drip for 15-20 minutes
Mannitol 3
Mannitol 3x250 cc
Mannitol
mannitol administration across all three dosages (3x125 cc, 2x250 cc, 3x250 cc) given as an IV drip for 15-20 minutes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mannitol
mannitol administration across all three dosages (3x125 cc, 2x250 cc, 3x250 cc) given as an IV drip for 15-20 minutes
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Glasgow Coma Scale (GCS) score indicating mild (14-13) or moderate (12-10)
Exclusion Criteria
* Multiple trauma with bleeding shock
* Diabetes mellitus
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universitas Diponegoro
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Taufik Saputra
Resident of Anesthesiology and Intensive Care, Medical Doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Aria P Hayanto, Sp.An-TI
Role: STUDY_DIRECTOR
Universitas Diponegoro
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dr. Kariadi Central General Hospital
Semarang, Central Java, Indonesia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1554/EC/KEPK-RSDK/2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.